Elevai Labs Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
0.0201
-0.0088 (-30.45%)
At close: Nov 4, 2024, 4:00 PM
0.0239
+0.0038 (18.91%)
After-hours: Nov 4, 2024, 7:59 PM EST
Elevai Labs Employees
Elevai Labs had 18 employees as of December 31, 2023.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
$137,408
Profits / Employee
-$263,928
Market Cap
992.46K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| cbdMD | 52 |
| Catheter Precision | 14 |
| Cyclacel Pharmaceuticals | 12 |
| Altamira Therapeutics | 10 |
| Revelation Biosciences | 9 |
| SCWorx | 7 |
| 60 Degrees Pharmaceuticals | 3 |
| SciSparc | 3 |
ELAB News
- 3 hours ago - Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewsWire
- 13 days ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - GlobeNewsWire
- 14 days ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - GlobeNewsWire
- 4 weeks ago - Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - GlobeNewsWire
- 4 weeks ago - REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire
- 4 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire
- 4 weeks ago - Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device - GlobeNewsWire
- 5 weeks ago - Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) - GlobeNewsWire